Eric. C. Frey
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Eric. C. Frey has a total of 122 co-authors. Here are the top co-authors by number of shared publications:
- Xin He
Department of Radiology, Johns Hopkins School of Medicine, Baltimore, MD 21287, USA
7 shared publications - George Sgouros
Johns Hopkins University
6 shared publications - Ye Li
Johns Hopkins University
5 shared publications - Yong Du
The Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins Medical School, Baltimore, MD, USA
5 shared publications - Benjamin M. W. Tsui
Department of Radiology, School of Medicine, Johns Hopkins University, Baltimore, MD, USA
4 shared publications - Wesley E. Bolch
University of Florida
4 shared publications
Latest Publications
- Open Access
TransMorph: Transformer for unsupervised medical image registration
In the last decade, convolutional neural networks (ConvNets) have been a major focus of research in medical image analysis. However, the performances of ConvNets may be limited by a lack of explicit consideration of the long-range spatial relationships in an image. Recently Vision Transformer architectures have been proposed to address the shortcomings of ConvNets and have produced state-of-the-art performances in many medical imaging applications. Transformers may be a strong candidate for image registration because their substantially larger receptive field enables a more precise comprehension of the spatial correspondence between moving and fixed images. Here, we present TransMorph, a hybrid Transformer-ConvNet model for volumetric medical image registration. This paper also presents diffeomorphic and Bayesian variants of TransMorph: the diffeomorphic variants ensure the topology-preserving deformations, and the Bayesian variant produces a well-calibrated registration uncertainty estimate. We extensively validated the proposed models using 3D medical images from three applications: inter-patient and atlas-to-patient brain MRI registration and phantom-to-CT registration. The proposed models are evaluated in comparison to a variety of existing registration methods and Transformer architectures. Qualitative and quantitative results demonstrate that the proposed Transformer-based model leads to a substantial performance improvement over the baseline methods, confirming the effectiveness of Transformers for medical image registration.
Open AccessTransMorph: Transformer for unsupervised medical image registration
In the last decade, convolutional neural networks (ConvNets) have been a major focus of research in medical image analysis. However, the performances of ConvNets may be limited by a lack of explicit consideration of the long-range spatial relationships in an image. Recently Vision Transformer architectures have been proposed to address the shortcomings of ConvNets and have produced state-of-the-art performances in many medical imaging applications. Transformers may be a strong candidate for image registration because their substantially larger receptive field enables a more precise comprehension of the spatial correspondence between moving and fixed images. Here, we present TransMorph, a hybrid Transformer-ConvNet model for volumetric medical image registration. This paper also presents diffeomorphic and Bayesian variants of TransMorph: the diffeomorphic variants ensure the topology-preserving deformations, and the Bayesian variant produces a well-calibrated registration uncertainty estimate. We extensively validated the proposed models using 3D medical images from three applications: inter-patient and atlas-to-patient brain MRI registration and phantom-to-CT registration. The proposed models are evaluated in comparison to a variety of existing registration methods and Transformer architectures. Qualitative and quantitative results demonstrate that the proposed Transformer-based model leads to a substantial performance improvement over the baseline methods, confirming the effectiveness of Transformers for medical image registration.
- Top Cited Papers
- 14 September 2022
- Published by Elsevier in Medical Image Analysis
- Vol. 82, 102615
TransMorph: Transformer for unsupervised medical image registration
- 14 September 2022
- Published by Elsevier in Medical Image Analysis
- Vol. 82, 102615
Top Cited PapersTransMorph: Transformer for unsupervised medical image registration
- Open Access
Prospective SPECT-CT Organ Dosimetry-Driven Radiation-Absorbed Dose Escalation Using the In-111 (111In)/Yttrium 90 (90Y) Ibritumomab Tiuxetan (Zevalin®) Theranostic Pair in Patients with Lymphoma at Myeloablative Dose Levels
Purpose: We prospectively evaluated the feasibility of SPECT-CT/planar organ dosimetry-based radiation dose escalation radioimmunotherapy in patients with recurrent non-Hodgkin’s lymphoma using the theranostic pair of 111In and 90Y anti-CD20 ibritumomab tiuxetan (Zevalin®) at myeloablative radiation-absorbed doses with autologous stem cell support. We also assessed acute non-hematopoietic toxicity and early tumor response in this two-center outpatient study. Methods: 24 patients with CD20-positive relapsed or refractory rituximab-sensitive, low-grade, mantle cell, or diffuse large-cell NHL, with normal organ function, platelet counts > 75,000/mm3, and 2) weekly for 4 consecutive weeks, then one dose of cyclophosphamide 2.5 g/m2 with filgrastim 10 mcg/kg/day until stem cell collection. Of these, 18 patients with successful stem cell collection (at least 2 × 106 CD34 cells/kg) proceeded to RIT. A dosimetric administration of 111In ibritumomab tiuxetan (185 MBq) followed by five sequential quantitative planar and one SPECT/CT scan was used to determine predicted organ radiation-absorbed dose. Two weeks later, 90Y ibritumomab tiuxetan was administered in an outpatient setting at a cohort- and patient-specific predicted organ radiation-absorbed dose guided by a Continuous Response Assessment (CRM) methodology with the following cohorts for dose escalation: 14.8 MBq/kg, and targeted 18, 24, 28, and 30.5 Gy to the liver. Autologous stem cell infusion occurred when the estimated marrow radiation-absorbed dose rate was predicted to be 90Y (range: 12.1–41.4 MBq/kg)) of ibritumomab tiuxetan that was required to deliver 10 Gy to the liver. Infused stem cells engrafted rapidly. The most common treatment-related toxicities were hematological and were reversible following stem cell infusion. No significant hepatotoxicity was seen. One patient died from probable treatment-related causes—pneumonia at day 27 post-transplant. One patient at dose level 18 Gy developed myelodysplastic syndrome (MDS), 4 patients required admission post-90Y RIT for febrile neutropenia, 16/18 patients receiving 90Y ibritumomab tiuxetan (89%) responded to the therapy, with 13 CR (72%) and 3/18 PR (17%), at 60 days post-treatment. Two patients had progressive disease at sixty days. One patient was lost to follow-up. Median time to progression was estimated to be at least 13 months. MTD to the liver is greater than 28 Gy, but the MTD was not reached as the study was terminated due to unexpected discontinuation of availability of the therapeutic agent. Conclusions: Patient-specific outpatient 90Y ibritumomab tiuxetan RIT with myeloablative doses of RIT up to a targeted 30.5 Gy to the liver is feasible, guided by prospective SPECT/CT + planar imaging with the theranostic pair of 111In and 90Y anti-CD20, with outpatient autologous stem cell transplant support. Administered activity over 5 times the standard FDA-approved activity was well-tolerated. The non-hematopoietic MTD in this study exceeds 28 Gy to the liver. Initial tumor responses were common at all dose levels. This study supports the feasibility of organ dosimetry-driven patient-specific dose escalation in the treatment of NHL with stem cell transplant and provides additional information on the radiation tolerance of the normal liver to radiopharmaceutical therapy.
Open AccessProspective SPECT-CT Organ Dosimetry-Driven Radiation-Absorbed Dose Escalation Using the In-111 (111In)/Yttrium 90 (90Y) Ibritumomab Tiuxetan (Zevalin®) Theranostic Pair in Patients with Lymphoma at Myeloablative Dose Levels
Purpose: We prospectively evaluated the feasibility of SPECT-CT/planar organ dosimetry-based radiation dose escalation radioimmunotherapy in patients with recurrent non-Hodgkin’s lymphoma using the theranostic pair of 111In and 90Y anti-CD20 ibritumomab tiuxetan (Zevalin®) at myeloablative radiation-absorbed doses with autologous stem cell support. We also assessed acute non-hematopoietic toxicity and early tumor response in this two-center outpatient study. Methods: 24 patients with CD20-positive relapsed or refractory rituximab-sensitive, low-grade, mantle cell, or diffuse large-cell NHL, with normal organ function, platelet counts > 75,000/mm3, and 2) weekly for 4 consecutive weeks, then one dose of cyclophosphamide 2.5 g/m2 with filgrastim 10 mcg/kg/day until stem cell collection. Of these, 18 patients with successful stem cell collection (at least 2 × 106 CD34 cells/kg) proceeded to RIT. A dosimetric administration of 111In ibritumomab tiuxetan (185 MBq) followed by five sequential quantitative planar and one SPECT/CT scan was used to determine predicted organ radiation-absorbed dose. Two weeks later, 90Y ibritumomab tiuxetan was administered in an outpatient setting at a cohort- and patient-specific predicted organ radiation-absorbed dose guided by a Continuous Response Assessment (CRM) methodology with the following cohorts for dose escalation: 14.8 MBq/kg, and targeted 18, 24, 28, and 30.5 Gy to the liver. Autologous stem cell infusion occurred when the estimated marrow radiation-absorbed dose rate was predicted to be 90Y (range: 12.1–41.4 MBq/kg)) of ibritumomab tiuxetan that was required to deliver 10 Gy to the liver. Infused stem cells engrafted rapidly. The most common treatment-related toxicities were hematological and were reversible following stem cell infusion. No significant hepatotoxicity was seen. One patient died from probable treatment-related causes—pneumonia at day 27 post-transplant. One patient at dose level 18 Gy developed myelodysplastic syndrome (MDS), 4 patients required admission post-90Y RIT for febrile neutropenia, 16/18 patients receiving 90Y ibritumomab tiuxetan (89%) responded to the therapy, with 13 CR (72%) and 3/18 PR (17%), at 60 days post-treatment. Two patients had progressive disease at sixty days. One patient was lost to follow-up. Median time to progression was estimated to be at least 13 months. MTD to the liver is greater than 28 Gy, but the MTD was not reached as the study was terminated due to unexpected discontinuation of availability of the therapeutic agent. Conclusions: Patient-specific outpatient 90Y ibritumomab tiuxetan RIT with myeloablative doses of RIT up to a targeted 30.5 Gy to the liver is feasible, guided by prospective SPECT/CT + planar imaging with the theranostic pair of 111In and 90Y anti-CD20, with outpatient autologous stem cell transplant support. Administered activity over 5 times the standard FDA-approved activity was well-tolerated. The non-hematopoietic MTD in this study exceeds 28 Gy to the liver. Initial tumor responses were common at all dose levels. This study supports the feasibility of organ dosimetry-driven patient-specific dose escalation in the treatment of NHL with stem cell transplant and provides additional information on the radiation tolerance of the normal liver to radiopharmaceutical therapy.
- 28 January 2021
- Published by SPIE-Intl Soc Optical Eng in Journal of Medical Imaging
- Vol. 8 (04) , 1-22
DeepAMO: a multi-slice, multi-view anthropomorphic model observer for visual detection tasks performed on volume images
The Journal of Medical Imaging allows for the peer-reviewed communication and archiving of fundamental and translational research, as well as applications, focused on medical imaging, a field that continues to benefit from technological improvements and yield biomedical advancements in the early detection, diagnostics, and therapy of disease as well as in the understanding of normal conditions.
- 28 January 2021
- Published by SPIE-Intl Soc Optical Eng in Journal of Medical Imaging
- Vol. 8 (04) , 1-22
DeepAMO: a multi-slice, multi-view anthropomorphic model observer for visual detection tasks performed on volume images
The Journal of Medical Imaging allows for the peer-reviewed communication and archiving of fundamental and translational research, as well as applications, focused on medical imaging, a field that continues to benefit from technological improvements and yield biomedical advancements in the early detection, diagnostics, and therapy of disease as well as in the understanding of normal conditions.
- 2 December 2020
- Published by IOP Publishing in Physics in Medicine & Biology
- Vol. 65 (23) , 235025
Dosimetric considerations of99mTc-MDP uptake within the epiphyseal plates of the long bones of pediatric patients
Skeletal scintigraphy is most performed in pediatric patients using the radiopharmaceutical 99m Tc labelled methylene diphosphonate ( 99m Tc-MDP). Reference biokinetic models for 99m Tc-MDP indicate 50% of the administered activity is uniformly localized to the interior bone surfaces (trabecular and cortical regions), yet imaging data clearly show some preferential uptake to the epiphyseal growth plates of the long bones. To explore the dosimetric consequences of these regional activity concentrations, we have modified mesh-type computational phantoms of the International Commission on Radiological Protection (ICRP) reference pediatric series to explicitly include geometric models of the epiphyseal growth plates (2 mm in thickness) within the left/right, distal/proximal ends of the humeri, radii, ulnae, femora, tibia, and fibulae. Bone mineral activity from the ICRP Publication 128 biokinetic model for 99m Tc-MDP (ICRP 2015) was then partitioned to the growth plates at values of 0.5%, 4.4%, 8.3%, 12.2%, 16.1%, and 20%. Radiation transport simulations were performed to compute 99m Tc S-values and organ dose coefficients to the soft tissues and to bone site-specific regions of spongiosa. As the percentage of bone activity assigned to the growth plates was increased (from 0.5% to 20%), absorbed doses to the soft tissue organs, active bone marrow, bone endosteum (BE), as well as the detriment-weighted dose, were shown to decrease from their nominal values (no substantial growth plate activity), while epiphyseal plate self-doses increased. In the 15 year old male phantom, moving from 0.5% to 20% relative bone activity within the epiphyseal plates resulted in a 15% reduction in active marrow (AM) and BE dose, a 10% reduction in mean soft tissue and detriment-weighted dose, and a 6.3-fold increase in epiphyseal plate self-dose. In the newborn female phantom, we observed a 18% decrease in AM and BE dose, a 10% decrease in mean soft tissue dose, a 15% decrease in detriment-weighted dose, and 12.8-fold increase in epiphyseal plate self-dose. Increases (to 3 mm) and decreases (to 1 mm) in the assumed growth plate thickness of our models were shown to impact only the growth plate self-dose. Future work in differential quantification of 99m Tc-MDP activity—growth plates versus other bone surfaces—is required to provide clinically realistic data on activity partitioning as a function of patient age, and perhaps skeletal site. The phantom series presented here may be used to develop more optimized age-related guidance on 99m Tc-MDP administered activities to children.
- 2 December 2020
- Published by IOP Publishing in Physics in Medicine & Biology
- Vol. 65 (23) , 235025
Dosimetric considerations of99mTc-MDP uptake within the epiphyseal plates of the long bones of pediatric patients
Skeletal scintigraphy is most performed in pediatric patients using the radiopharmaceutical 99m Tc labelled methylene diphosphonate ( 99m Tc-MDP). Reference biokinetic models for 99m Tc-MDP indicate 50% of the administered activity is uniformly localized to the interior bone surfaces (trabecular and cortical regions), yet imaging data clearly show some preferential uptake to the epiphyseal growth plates of the long bones. To explore the dosimetric consequences of these regional activity concentrations, we have modified mesh-type computational phantoms of the International Commission on Radiological Protection (ICRP) reference pediatric series to explicitly include geometric models of the epiphyseal growth plates (2 mm in thickness) within the left/right, distal/proximal ends of the humeri, radii, ulnae, femora, tibia, and fibulae. Bone mineral activity from the ICRP Publication 128 biokinetic model for 99m Tc-MDP (ICRP 2015) was then partitioned to the growth plates at values of 0.5%, 4.4%, 8.3%, 12.2%, 16.1%, and 20%. Radiation transport simulations were performed to compute 99m Tc S-values and organ dose coefficients to the soft tissues and to bone site-specific regions of spongiosa. As the percentage of bone activity assigned to the growth plates was increased (from 0.5% to 20%), absorbed doses to the soft tissue organs, active bone marrow, bone endosteum (BE), as well as the detriment-weighted dose, were shown to decrease from their nominal values (no substantial growth plate activity), while epiphyseal plate self-doses increased. In the 15 year old male phantom, moving from 0.5% to 20% relative bone activity within the epiphyseal plates resulted in a 15% reduction in active marrow (AM) and BE dose, a 10% reduction in mean soft tissue and detriment-weighted dose, and a 6.3-fold increase in epiphyseal plate self-dose. In the newborn female phantom, we observed a 18% decrease in AM and BE dose, a 10% decrease in mean soft tissue dose, a 15% decrease in detriment-weighted dose, and 12.8-fold increase in epiphyseal plate self-dose. Increases (to 3 mm) and decreases (to 1 mm) in the assumed growth plate thickness of our models were shown to impact only the growth plate self-dose. Future work in differential quantification of 99m Tc-MDP activity—growth plates versus other bone surfaces—is required to provide clinically realistic data on activity partitioning as a function of patient age, and perhaps skeletal site. The phantom series presented here may be used to develop more optimized age-related guidance on 99m Tc-MDP administered activities to children.
- 25 November 2020
- Published by IOP Publishing in Physics in Medicine & Biology
- Vol. 65 (23) , 235026
Body morphometry appropriate computational phantoms for dose and risk optimization in pediatric renal imaging with Tc-99m DMSA and Tc-99m MAG3
Current guidelines for administered activity (AA) in pediatric nuclear medicine imaging studies are based on a 2016 harmonization of the 2010 North American Consensus guidelines and the 2007 European Association of Nuclear Medicine pediatric dosage card. These guidelines assign AA scaled to patient body mass, with further constraints on maximum and minimum values of radiopharmaceutical activity. These guidelines, however, are not formulated based upon a rigor-ous evaluation of diagnostic image quality. In a recent study of the renal cortex imaging agent 99mTc-DMSA (Li Y et al 2019), body mass-based dosing guidelines were shown to not give the same level of image quality for patients of differing body mass. Their data suggest that patient girth at the level of the kidneys may be a better morphometric parameter to consider when selecting AA for renal nuclear medicine imaging. The objective of the present work was thus to develop a dedicated series of computational phantoms to support image quality and organ dose studies in pediatric renal imaging using 99mTc-DMSA or 99mTc-MAG3. The final library consists of 50 male and female phantoms of ages 0 to 15 years, with percentile variations (5th to 95th) in waist circumference (WC) at each age. For each phantom, nominal values of kidney volume, length, and depth were incorporated into the phantom design. Organ absorbed doses, detriment-weighted doses, and stochastic risks were assessed using ICRP reference biokinetic models for both agents. In Monte Carlo radiation transport simulations, organ doses for these agents yielded detriment-weighted dose coefficients (mSv/MBq) that were in general larger than current ICRP values of the effective dose coefficients (age and WC-averaged ratios of eDW/e were 1.40 for the male phantoms and 1.49 for the female phantoms). Values of risk index (ratio of radiation-induced to natural background cancer incidence risk x 100) varied between 0.062 (newborns) to 0.108 (15-year-olds) for 99mTc-DMSA and between 0.026 (newborns) to 0.122 (15-year-olds) for 99mTc-MAG3. Using tallies of photon exit fluence as a rough surrogate for uniform image quality, our study demonstrated that through body region-of-interest optimization of AA, there is the potential for further dose and risk reductions of between factors of 1.5 to 3.0 beyond simple weight-based dosing guidance.
- 25 November 2020
- Published by IOP Publishing in Physics in Medicine & Biology
- Vol. 65 (23) , 235026
Body morphometry appropriate computational phantoms for dose and risk optimization in pediatric renal imaging with Tc-99m DMSA and Tc-99m MAG3
Current guidelines for administered activity (AA) in pediatric nuclear medicine imaging studies are based on a 2016 harmonization of the 2010 North American Consensus guidelines and the 2007 European Association of Nuclear Medicine pediatric dosage card. These guidelines assign AA scaled to patient body mass, with further constraints on maximum and minimum values of radiopharmaceutical activity. These guidelines, however, are not formulated based upon a rigor-ous evaluation of diagnostic image quality. In a recent study of the renal cortex imaging agent 99mTc-DMSA (Li Y et al 2019), body mass-based dosing guidelines were shown to not give the same level of image quality for patients of differing body mass. Their data suggest that patient girth at the level of the kidneys may be a better morphometric parameter to consider when selecting AA for renal nuclear medicine imaging. The objective of the present work was thus to develop a dedicated series of computational phantoms to support image quality and organ dose studies in pediatric renal imaging using 99mTc-DMSA or 99mTc-MAG3. The final library consists of 50 male and female phantoms of ages 0 to 15 years, with percentile variations (5th to 95th) in waist circumference (WC) at each age. For each phantom, nominal values of kidney volume, length, and depth were incorporated into the phantom design. Organ absorbed doses, detriment-weighted doses, and stochastic risks were assessed using ICRP reference biokinetic models for both agents. In Monte Carlo radiation transport simulations, organ doses for these agents yielded detriment-weighted dose coefficients (mSv/MBq) that were in general larger than current ICRP values of the effective dose coefficients (age and WC-averaged ratios of eDW/e were 1.40 for the male phantoms and 1.49 for the female phantoms). Values of risk index (ratio of radiation-induced to natural background cancer incidence risk x 100) varied between 0.062 (newborns) to 0.108 (15-year-olds) for 99mTc-DMSA and between 0.026 (newborns) to 0.122 (15-year-olds) for 99mTc-MAG3. Using tallies of photon exit fluence as a rough surrogate for uniform image quality, our study demonstrated that through body region-of-interest optimization of AA, there is the potential for further dose and risk reductions of between factors of 1.5 to 3.0 beyond simple weight-based dosing guidance.
- 24 November 2020
- Published by IOP Publishing in Physics in Medicine & Biology
- Vol. 65 (23) , 235015
Specific absorbed fractions and radionuclide S-values for tumors of varying size and composition
Accurate estimates of tumor absorbed dose are essential for the evaluation of treatment efficacy in radiopharmaceutical cancer therapy. Although tumor dosimetry via the MIRD schema has been previously investigated, prior studies have been limited to the consideration of soft-tissue tumors. In the present study, specific absorbed fractions (SAFs) for monoenergetic photons, electrons, and alpha particles in tumors of varying compositions were computed using Monte Carlo simulations in MCNPX after which self-irradiation S-values for 22 radionuclides (along with 14 additional alpha-emitter progeny) were generated for tumors of both varying size and tissue composition. The tumors were modeled as spheres with radii ranging from 0.10 cm to 6.0 cm and with compositions varying from 100% soft tissue (ST) to 100% mineral bone (MB). The energies of the photons and electrons were varied on a logarithm energy grid from 10 keV to 10 MeV. The energies of alpha particles were varied along a linear energy grid from 0.5 MeV to 12 MeV. In all cases, a homogenous activity distribution was assumed throughout the tumor volume. Furthermore, to assess the effect of tumor shape, several ellipsoidal tumors of different compositions were modeled and absorbed fractions were computed for monoenergetic electrons and photons. S-values were then generated using detailed decay data from the 2008 MIRD Monograph on Radionuclide Data and Decay Schemes. Our study results demonstrate that a soft-tissue model yields relative errors of 25% and 71% in the absorbed fraction assigned to uniform sources of 1.5 MeV electrons and 100 keV photons, respectively, localized within a 1 cm diameter tumor of MB. The data further show that absorbed fractions for moderate ellipsoids can be well approximated by a spherical shape of equal mass within a relative error of < 8%. S-values for 22 radionuclides (and their daughter progeny) were computed with results demonstrating how relative errors in SAFs could propagate to relative errors in tumor dose estimates as high as 86%. A comprehensive data set of radionuclide S-values by tumor size and tissue composition is provided for application of the MIRD schema for tumor dosimetry in radiopharmaceutical therapy.
- 24 November 2020
- Published by IOP Publishing in Physics in Medicine & Biology
- Vol. 65 (23) , 235015
Specific absorbed fractions and radionuclide S-values for tumors of varying size and composition
Accurate estimates of tumor absorbed dose are essential for the evaluation of treatment efficacy in radiopharmaceutical cancer therapy. Although tumor dosimetry via the MIRD schema has been previously investigated, prior studies have been limited to the consideration of soft-tissue tumors. In the present study, specific absorbed fractions (SAFs) for monoenergetic photons, electrons, and alpha particles in tumors of varying compositions were computed using Monte Carlo simulations in MCNPX after which self-irradiation S-values for 22 radionuclides (along with 14 additional alpha-emitter progeny) were generated for tumors of both varying size and tissue composition. The tumors were modeled as spheres with radii ranging from 0.10 cm to 6.0 cm and with compositions varying from 100% soft tissue (ST) to 100% mineral bone (MB). The energies of the photons and electrons were varied on a logarithm energy grid from 10 keV to 10 MeV. The energies of alpha particles were varied along a linear energy grid from 0.5 MeV to 12 MeV. In all cases, a homogenous activity distribution was assumed throughout the tumor volume. Furthermore, to assess the effect of tumor shape, several ellipsoidal tumors of different compositions were modeled and absorbed fractions were computed for monoenergetic electrons and photons. S-values were then generated using detailed decay data from the 2008 MIRD Monograph on Radionuclide Data and Decay Schemes. Our study results demonstrate that a soft-tissue model yields relative errors of 25% and 71% in the absorbed fraction assigned to uniform sources of 1.5 MeV electrons and 100 keV photons, respectively, localized within a 1 cm diameter tumor of MB. The data further show that absorbed fractions for moderate ellipsoids can be well approximated by a spherical shape of equal mass within a relative error of < 8%. S-values for 22 radionuclides (and their daughter progeny) were computed with results demonstrating how relative errors in SAFs could propagate to relative errors in tumor dose estimates as high as 86%. A comprehensive data set of radionuclide S-values by tumor size and tissue composition is provided for application of the MIRD schema for tumor dosimetry in radiopharmaceutical therapy.
- Open Access
Medical Image Segmentation via Unsupervised Convolutional Neural Network
For the majority of the learning-based segmentation methods, a large quantity of high-quality training data is required. In this paper, we present a novel learning-based segmentation model that could be trained semi- or un- supervised. Specifically, in the unsupervised setting, we parameterize the Active contour without edges (ACWE) framework via a convolutional neural network (ConvNet), and optimize the parameters of the ConvNet using a self-supervised method. In another setting (semi-supervised), the auxiliary segmentation ground truth is used during training. We show that the method provides fast and high-quality bone segmentation in the context of single-photon emission computed tomography (SPECT) image.
Open AccessMedical Image Segmentation via Unsupervised Convolutional Neural Network
For the majority of the learning-based segmentation methods, a large quantity of high-quality training data is required. In this paper, we present a novel learning-based segmentation model that could be trained semi- or un- supervised. Specifically, in the unsupervised setting, we parameterize the Active contour without edges (ACWE) framework via a convolutional neural network (ConvNet), and optimize the parameters of the ConvNet using a self-supervised method. In another setting (semi-supervised), the auxiliary segmentation ground truth is used during training. We show that the method provides fast and high-quality bone segmentation in the context of single-photon emission computed tomography (SPECT) image.
- Open Access
- 1 March 2019
- Published by Elsevier in Journal of Medical Imaging and Radiation Sciences
- Vol. 50 (1) , S34
Targeted Alpha-emitter Therapy of Neuroendocrine Tumors using 212Pb-octreotate (AlphaMedix TM)
- 1 March 2019
- Published by Elsevier in Journal of Medical Imaging and Radiation Sciences
- Vol. 50 (1) , S34
Open AccessTargeted Alpha-emitter Therapy of Neuroendocrine Tumors using 212Pb-octreotate (AlphaMedix TM)
- 16 February 2017
- Published by Wiley in Medical Physics
- Vol. 44 (5) , 1707-1717
Simplifying volumes‐of‐interest (VOIs) definition in quantitative SPECT: Beyond manual definition of 3D whole‐organ VOIs
Purpose We investigated the feasibility of using simpler methods than manual whole‐organ volume‐of‐interest (VOI) definition to estimate the organ activity concentration in single photon emission computed tomography (SPECT) in cases where the activity in the organ can be assumed to be uniformly distributed on the scale of the voxel size. In particular, we investigated an anatomic region‐of‐interest (ROI) defined in a single transaxial slice, and a single sphere placed inside the organ boundaries. Methods The evaluation was carried out using Monte Carlo simulations based on patient indium 111In pentetreotide SPECT and computed tomography (CT) images. We modeled constant activity concentrations in each organ, validating this assumption by comparing the distribution of voxel values inside the organ VOIs of the simulated data with the patient data. We simulated projection data corresponding to 100, 50, and 25% of the clinical count level to study the effects of noise level due to shortened acquisition time. Images were reconstructed using a previously validated quantitative SPECT reconstruction method. The evaluation was performed in terms of the accuracy and precision of the activity concentration estimates. Results The results demonstrated that the non‐uniform image intensity observed in the reconstructed images in the organs with normal uptake was consistent with uniform activity concentration in the organs on the scale of the voxel size; observed non‐uniformities in image intensity were due to a combination of partial‐volume effects at the boundaries of the organ, artifacts in the reconstructed image due to collimator‐detector response compensation, and noise. Using an ROI defined in a single transaxial slice produced similar biases compared to the three‐dimensional (3D) whole‐organ VOIs, provided that the transaxial slice was near the central plane of the organ and that the pixels from the organ boundaries were not included in the ROI. Although this slice method was sensitive to noise, biases were less than 10% for all the noise levels studied. The use of spherical VOIs was more sensitive to noise. The method was more accurate for larger spheres and larger organs such as the liver in comparison to the kidneys. Biases lower than 7% were found in the liver when using large enough spheres (radius ≥ 28 mm), regardless of the position, of the VOI inside the organ even with shortened acquisition times. The biases were more position‐dependent for smaller organs. Conclusions Both of the simpler methods provided suitable surrogates in terms of accuracy and precision. The results suggested that a spherical VOI was more appropriate for estimating the activity concentration in larger organs such as the liver, regardless of the position of the sphere inside the organ. Larger spheres resulted in better estimates. A single‐slice ROI was more suitable for activity estimation in smaller organs such as the kidneys, providing that the transaxial slice selected was near the central plane of the organ and that voxels from the organ boundaries were excluded. Under those conditions, activity concentrations with biases lower than 5% were observed for all the studied count levels and coefficients of variation were less than 9% and 5% for the 25% and 100% count levels, respectively.
- 16 February 2017
- Published by Wiley in Medical Physics
- Vol. 44 (5) , 1707-1717
Simplifying volumes‐of‐interest (VOIs) definition in quantitative SPECT: Beyond manual definition of 3D whole‐organ VOIs
Purpose We investigated the feasibility of using simpler methods than manual whole‐organ volume‐of‐interest (VOI) definition to estimate the organ activity concentration in single photon emission computed tomography (SPECT) in cases where the activity in the organ can be assumed to be uniformly distributed on the scale of the voxel size. In particular, we investigated an anatomic region‐of‐interest (ROI) defined in a single transaxial slice, and a single sphere placed inside the organ boundaries. Methods The evaluation was carried out using Monte Carlo simulations based on patient indium 111In pentetreotide SPECT and computed tomography (CT) images. We modeled constant activity concentrations in each organ, validating this assumption by comparing the distribution of voxel values inside the organ VOIs of the simulated data with the patient data. We simulated projection data corresponding to 100, 50, and 25% of the clinical count level to study the effects of noise level due to shortened acquisition time. Images were reconstructed using a previously validated quantitative SPECT reconstruction method. The evaluation was performed in terms of the accuracy and precision of the activity concentration estimates. Results The results demonstrated that the non‐uniform image intensity observed in the reconstructed images in the organs with normal uptake was consistent with uniform activity concentration in the organs on the scale of the voxel size; observed non‐uniformities in image intensity were due to a combination of partial‐volume effects at the boundaries of the organ, artifacts in the reconstructed image due to collimator‐detector response compensation, and noise. Using an ROI defined in a single transaxial slice produced similar biases compared to the three‐dimensional (3D) whole‐organ VOIs, provided that the transaxial slice was near the central plane of the organ and that the pixels from the organ boundaries were not included in the ROI. Although this slice method was sensitive to noise, biases were less than 10% for all the noise levels studied. The use of spherical VOIs was more sensitive to noise. The method was more accurate for larger spheres and larger organs such as the liver in comparison to the kidneys. Biases lower than 7% were found in the liver when using large enough spheres (radius ≥ 28 mm), regardless of the position, of the VOI inside the organ even with shortened acquisition times. The biases were more position‐dependent for smaller organs. Conclusions Both of the simpler methods provided suitable surrogates in terms of accuracy and precision. The results suggested that a spherical VOI was more appropriate for estimating the activity concentration in larger organs such as the liver, regardless of the position of the sphere inside the organ. Larger spheres resulted in better estimates. A single‐slice ROI was more suitable for activity estimation in smaller organs such as the kidneys, providing that the transaxial slice selected was near the central plane of the organ and that voxels from the organ boundaries were excluded. Under those conditions, activity concentrations with biases lower than 5% were observed for all the studied count levels and coefficients of variation were less than 9% and 5% for the 25% and 100% count levels, respectively.